Your browser doesn't support javascript.
ZRC3308 Monoclonal Antibody Cocktail Shows Protective Efficacy in Syrian Hamsters against SARS-CoV-2 Infection.
Yadav, Pragya D; Mendiratta, Sanjeev Kumar; Mohandas, Sreelekshmy; Singh, Arun K; Abraham, Priya; Shete, Anita; Bandyopadhyay, Sanjay; Kumar, Sanjay; Parikh, Aashini; Kalita, Pankaj; Sharma, Vibhuti; Pandya, Hardik; Patel, Chirag G; Patel, Mihir; Soni, Swagat; Giri, Suresh; Jain, Mukul.
  • Yadav PD; Indian Council of Medical Research-National Institute of Virology, Pune 411021, India.
  • Mendiratta SK; Zydus Research Centre, Cadila Healthcare Limited, Ahmedabad 382481, India.
  • Mohandas S; Indian Council of Medical Research-National Institute of Virology, Pune 411021, India.
  • Singh AK; Zydus Research Centre, Cadila Healthcare Limited, Ahmedabad 382481, India.
  • Abraham P; Indian Council of Medical Research-National Institute of Virology, Pune 411021, India.
  • Shete A; Indian Council of Medical Research-National Institute of Virology, Pune 411021, India.
  • Bandyopadhyay S; Zydus Research Centre, Cadila Healthcare Limited, Ahmedabad 382481, India.
  • Kumar S; Department of Neurosurgery, Command Hospital (Southern Command), Armed Forces Medical College (AFMC), Pune 411040, India.
  • Parikh A; Zydus Research Centre, Cadila Healthcare Limited, Ahmedabad 382481, India.
  • Kalita P; Zydus Research Centre, Cadila Healthcare Limited, Ahmedabad 382481, India.
  • Sharma V; Zydus Research Centre, Cadila Healthcare Limited, Ahmedabad 382481, India.
  • Pandya H; Zydus Research Centre, Cadila Healthcare Limited, Ahmedabad 382481, India.
  • Patel CG; Zydus Research Centre, Cadila Healthcare Limited, Ahmedabad 382481, India.
  • Patel M; Zydus Research Centre, Cadila Healthcare Limited, Ahmedabad 382481, India.
  • Soni S; Zydus Research Centre, Cadila Healthcare Limited, Ahmedabad 382481, India.
  • Giri S; Zydus Research Centre, Cadila Healthcare Limited, Ahmedabad 382481, India.
  • Jain M; Zydus Research Centre, Cadila Healthcare Limited, Ahmedabad 382481, India.
Viruses ; 13(12)2021 12 03.
Article in English | MEDLINE | ID: covidwho-1555015
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT
We have developed a monoclonal antibody (mAb) cocktail (ZRC-3308) comprising of ZRC3308-A7 and ZRC3308-B10 in the ratio 11 for COVID-19 treatment. The mAbs were designed to have reduced immune effector functions and increased circulation half-life. mAbs showed good binding affinities to non-competing epitopes on RBD of SARS-CoV-2 spike protein and were found neutralizing SARS-CoV-2 variants B.1, B.1.1.7, B.1.351, B.1.617.2, and B.1.617.2 AY.1 in vitro. The mAb cocktail demonstrated effective prophylactic and therapeutic activity against SARS-CoV-2 infection in Syrian hamsters. The antibody cocktail appears to be a promising candidate for prophylactic use and for therapy in early COVID-19 cases that have not progressed to severe disease.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Monoclonal, Humanized / SARS-CoV-2 / COVID-19 Type of study: Observational study Topics: Variants Limits: Animals / Humans Language: English Year: 2021 Document Type: Article Affiliation country: V13122424

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Monoclonal, Humanized / SARS-CoV-2 / COVID-19 Type of study: Observational study Topics: Variants Limits: Animals / Humans Language: English Year: 2021 Document Type: Article Affiliation country: V13122424